James Simon

Summary

Publications

  1. ncbi request reprint Estrogen replacement therapy: effects on the endogenous androgen milieu
    James A Simon
    George Washington University School of Medicine, Washington, D C, USA
    Fertil Steril 77:S77-82. 2002
  2. ncbi request reprint Estradiol topical emulsion for the treatment of moderate-to-severe vasomotor symptoms associated with menopause
    James A Simon
    George Washington University, 1850 M Street NW, Suite 450, Washington DC 20036, USA
    Womens Health (Lond Engl) 3:29-37. 2007
  3. ncbi request reprint Skeletal consequences of hormone therapy discontinuance: a systematic review
    James A Simon
    Obstetrics and Gynecology, George Washington University, 1850 M Street, Ste 450, Washington, DC 20036, USA
    Obstet Gynecol Surv 61:115-24. 2006
  4. ncbi request reprint Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy
    James A Simon
    Women s Health Research Center, Laurel, MD 20707, USA
    Am J Obstet Gynecol 188:92-9. 2003
  5. ncbi request reprint Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder
    James Simon
    Women s Health Research Center J S, Laurel, Maryland 20707, USA
    J Clin Endocrinol Metab 90:5226-33. 2005
  6. doi request reprint Endometrial safety of ultra-low-dose estradiol vaginal tablets
    James Simon
    Women s Health and Research Consultants, Washington, DC 20036, USA
    Obstet Gynecol 116:876-83. 2010
  7. doi request reprint Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet
    James Simon
    Women s Health and Research Consultants, Washington, DC 20036, USA
    Obstet Gynecol 112:1053-60. 2008
  8. ncbi request reprint Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials
    Jean P Rowan
    Clinical Research Consultancy, Ann Arbor, Michigan, and Department of Obstetrics and Gynecology, George Washington University, Washington, DC, USA
    Clin Ther 28:921-32. 2006
  9. ncbi request reprint Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms
    James A Simon
    George Washington University School of Medicine, Washington, DC 20036, USA
    Menopause 13:222-31. 2006
  10. ncbi request reprint Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women
    James A Simon
    Obstetrics and Gynecology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia 20036, USA
    Fertil Steril 90:1132-8. 2008

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Estrogen replacement therapy: effects on the endogenous androgen milieu
    James A Simon
    George Washington University School of Medicine, Washington, D C, USA
    Fertil Steril 77:S77-82. 2002
    ..To review the impact of exogenous estrogen replacement therapy (ERT) on the production, binding, and metabolism of ovarian and adrenal androgens...
  2. ncbi request reprint Estradiol topical emulsion for the treatment of moderate-to-severe vasomotor symptoms associated with menopause
    James A Simon
    George Washington University, 1850 M Street NW, Suite 450, Washington DC 20036, USA
    Womens Health (Lond Engl) 3:29-37. 2007
    ..This formulation provides patients with a cosmetic-like treatment option that is effective and safe, delivers stable systemic estradiol levels, and may promote overall treatment compliance...
  3. ncbi request reprint Skeletal consequences of hormone therapy discontinuance: a systematic review
    James A Simon
    Obstetrics and Gynecology, George Washington University, 1850 M Street, Ste 450, Washington, DC 20036, USA
    Obstet Gynecol Surv 61:115-24. 2006
    ....
  4. ncbi request reprint Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy
    James A Simon
    Women s Health Research Center, Laurel, MD 20707, USA
    Am J Obstet Gynecol 188:92-9. 2003
    ....
  5. ncbi request reprint Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder
    James Simon
    Women s Health Research Center J S, Laurel, Maryland 20707, USA
    J Clin Endocrinol Metab 90:5226-33. 2005
    ..Hypoactive sexual desire disorder (HSDD) is one of the most common sexual problems reported by women, but few studies have been conducted to evaluate treatments for this condition...
  6. doi request reprint Endometrial safety of ultra-low-dose estradiol vaginal tablets
    James Simon
    Women s Health and Research Consultants, Washington, DC 20036, USA
    Obstet Gynecol 116:876-83. 2010
    ..To evaluate the endometrial hyperplasia and carcinoma rate after 52-week treatment with ultra-low-dose 10-microgram 17β-estradiol vaginal tablets in postmenopausal women with vaginal atrophy...
  7. doi request reprint Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet
    James Simon
    Women s Health and Research Consultants, Washington, DC 20036, USA
    Obstet Gynecol 112:1053-60. 2008
    ..To evaluate the efficacy of ultra-low-dose 10-microgram 17beta-estradiol (E2) vaginal tablets for treatment of vaginal atrophy...
  8. ncbi request reprint Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials
    Jean P Rowan
    Clinical Research Consultancy, Ann Arbor, Michigan, and Department of Obstetrics and Gynecology, George Washington University, Washington, DC, USA
    Clin Ther 28:921-32. 2006
    ....
  9. ncbi request reprint Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms
    James A Simon
    George Washington University School of Medicine, Washington, DC 20036, USA
    Menopause 13:222-31. 2006
    ..To assess the efficacy and safety of topical micellar nanoparticle estradiol emulsion (MNPEE; Estrasorb; Novavax, Inc., Malvern, PA) in postmenopausal women with moderate to severe vasomotor symptoms...
  10. ncbi request reprint Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women
    James A Simon
    Obstetrics and Gynecology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia 20036, USA
    Fertil Steril 90:1132-8. 2008
    ..To evaluate the safety and efficacy of synthetic conjugated estrogens B (SCE-B; 0.3 mg/d) for 12 weeks in the treatment of vulvovaginal atrophy in symptomatic, postmenopausal women...
  11. ncbi request reprint Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial
    James A Simon
    Obstet Gynecol 101:1020; author reply 1020-1. 2003
  12. ncbi request reprint Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial
    Glenn D Braunstein
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, Calif, 90048, USA
    Arch Intern Med 165:1582-9. 2005
    ..Oophorectomy reduces serum testosterone levels. We studied the efficacy and safety of transdermal testosterone in treating hypoactive sexual desire disorder in surgically menopausal women...
  13. ncbi request reprint A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms
    Marc F Botteman
    Abt Associates Inc, Bethesda, MD, USA Pfizer Inc, New York, NY, USA
    Menopause 11:343-55. 2004
    ..625 mg/day of conjugated estrogens plus 2.5 mg of medroxyprogesterone (0.625/2.5 CEE/MPA) compared with no therapy for the management of moderate-to-severe vasomotor symptoms...
  14. ncbi request reprint Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial
    James A Simon
    George Washington University, Washington, DC, USA
    Obstet Gynecol 109:588-96. 2007
    ..To investigate safety and efficacy and identify the lowest effective dose of a new transdermal estradiol (E2) gel for relief of menopausal symptoms in a population of postmenopausal women...
  15. ncbi request reprint Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study
    James A Simon
    George Washington University School of Medicine, Washington, DC, USA
    Clin Ther 24:1871-86. 2002
    ..Alendronate, an oral bisphosphonate, is available for the treatment of osteoporosis in a 70-mg once-weekly and a 10-mg once-daily formulation...
  16. ncbi request reprint Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen
    James A Simon
    George Washington University, 1850 M Street, NW, Suite 450, Washington, DC 20036, USA
    Expert Opin Investig Drugs 16:2005-20. 2007
    ....
  17. ncbi request reprint Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in luteinizing hormone and follicle-stimulating hormone with age
    Rebecca J Ferrell
    Center for Population and Health, Georgetown University, Washington, DC, USA
    Menopause 14:29-37. 2007
    ..This study describes age-related changes in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a 5-year prospective study of reproductive aging...
  18. ncbi request reprint Treatment of osteoporosis: combination therapies
    James A Simon
    Department of Obstetrics and Gynecology, George Washington University, School of Medicine, Washington, D C, USA
    Int J Fertil Womens Med 48:127-31; discussion 137-8. 2003
    ..The potential synergistic effects of combination therapies are just beginning to be explored. Until more information is available, recommendations for use of combination therapies should be limited to specific clinical situations...
  19. ncbi request reprint A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users
    James A Simon
    Department of Obstetrics and Gynecology, George Washington University School of Medicine, Washington, DC, USA
    Menopause 10:37-44. 2003
    ..To estimate the rate of therapy continuation among women using six different hormone replacement therapies (HRTs)...
  20. ncbi request reprint Counseling patients who elect to discontinue hormone therapy
    James A Simon
    Department of Obstetrics and Gynecology, George Washington University, School of Medicine, Washington, D C, USA
    Int J Fertil Womens Med 48:111-6; discussion 137-8. 2003
    ..Counseling patients on which treatment options: raloxifene, bisphosphonate, calcitonin, or PTH are most appropriate for their situation is important to long-term compliance and a satisfactory reduction in fracture risk...
  21. ncbi request reprint Prevention and management of osteoporosis
    James A Simon
    Department of Ob Gyn, The George Washington University School of Medicine, Washington, DC, USA
    Clin Cornerstone . 2003
    ....
  22. ncbi request reprint Does osteopenia warrant treatment?
    James A Simon
    George Washington University School of Medicine, Washington, DC 20036 5803, USA
    Menopause 12:639-48. 2005
    ..Initiation of antiresorptive therapy known to provide rapid efficacy can be particularly important in achieving the treatment goal in appropriate osteopenic women...